Healthcare Innovations & 2015 JP Morgan Conference (JPM)

REGISTRATION IS NOW CLOSED DUE TO SPACE RESTRICTIONS OF THE VENUE. IF YOU WISH TO WALK-IN, PLEASE CONTACT MAGGIE WU maggie_wu@yahoo.com TO SEE IF YOU CAN BE ACCOMMODATED.

Cost: $15.00 online / $20 walk-ins

REGISTRATION IS NOW CLOSED DUE TO SPACE RESTRICTIONS OF THE VENUE.  IF YOU WISH TO WALK-IN, PLEASE CONTACT MAGGIE WU maggie_wu@yahoo.com TO SEE IF YOU CAN BE ACCOMMODATED.


The annual JP Morgan’s Healthcare Conference (JPM) in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. Each year hundreds of organizations, both public and private companies as well as academic institutions, deliver presentations to over 4,000 investors. In addition, thousands in biotech descend upon San Francisco to network, attend meetings and gain an inside view even if they can’t secure an official conference invite.

The University of Chicago Life Science Affinity Group (LSAG) will be hosting a panel discussion and networking reception to help JPM attendees and local alumni to get to know each better professionally and socially. We want to leverage the extraordinary reunion of alumni coming from all over the world to have an in-depth conversation about healthcare innovations and the implications of JPM.

The panel of speakers representing the pharmaceutical, venture capital, health administration and consultants will have a roundtable discussion regarding:

• Insiders’ recap of their experience at 2015 JP Morgan (JPM) Healthcare Conference
• Healthcare innovations inside and outside of JPM
• Who are the key players and why
• What would drive the roadmap to market success
• Implications for consumers and investors

Please address any questions to event organizer, Maggie Wu, MBA'87 at maggie_wu@yahoo.com

Speakers include:

 

  • Alexander Johns (moderator), AB'83 MBA'87, Chairman of Arete Strategies
  • Annie De Groot, LAB'73 MD'83, CEO of EpiVax, "Cutting edge vaccines to the developing world"
  • Stephen Isaacs, CEO of Aduro, "Innovations in cancer immunotherapy"
  • Barry Ticho, MD'87 PhD'88, Head of external R&D Innovations, Pfizer, "Strategic alliance with big pharmaceutical companies"
  • James Wilkins, President of Fair Access Medicines, "Ebola & successful entrepreneurs doing well and doing good"
  • Scott M. Matthews, Vice Presidetn of Product Marketing, Castlight Health, "How does price transparency change health care"

Biographies:


Anne S. De Groot earned her B.S. at Smith College, her M.D. at the Pritzker School of Medicine, University of Chicago. 
She worked on field campaigns to vaccinate against measles in Zaire, then trained in Internal Medicine (New England
Medical Center), was a NRSA fellow in tropical medicine and vaccinology at NIH (LPD) and underwent specialty training
n infectious disease again at New England Medical Center. She worked at Brown University 1993-2008, established EpiVax
with business partner Bill Martin (1998) and has served as CEO/CSO since.
  In 2008 she was invited to lead the Institute for
Immunology and Informatics (iCubed) and subsequently was awarded $13M in funding to establish the iCubed as a
Center of Excellence in Computational Vaccinology. She was recognized as one of the 50 most influential people in
vaccinology in 2014.


Alexander Johns,
Chairman of Arete Strategies, brings over two decades of bio-pharma strategy consulting experience
from industry leaders, including many of the the most successful launches, to start-up companies. Alexander earned his
MBA from the University of Chicago in 1987 and joined Frank Lynn & Associates where he began bio-pharma strategy
consulting in 1990. Alexander continued to expand his biotech clientele as Founder & Principal at Quality Directions
1991-1995 and then as Founder & Chairman of bioStrategies Group 1995-2011. Alexander now leads Areté Strategies as
Founder & Chairman.

Stephen Isaacs, prior to Aduro, Mr. Isaacs was founder (1991), President and CEO of Cerus Corporation (NASD: CERS),
a biomedical products company commercializing the Intercept Blood Systems.  During his tenure at Cerus, Mr. Isaacs
grew the company from three to over two hundred and fifty employees. He raised over $650M, negotiated a $200M
partnership with Baxter International, took Cerus public and developed two marketed products.  Prior to Cerus,
Mr. Isaacs was the CEO of a number of small biotech companies where he negotiated contracts and partnerships with
Cetus Corporation, Chiron Corporation, Eastman Kodak, Hoffmann-La Roche and Applied Biosystems. He is an
international expert in psoralen photochemistry, and from 1978 to 1986 held a non-teaching faculty position in the
Department of Chemistry at UC Berkeley.
  Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an
inventor on over 40 issued patents. He holds a BA degree in Biochemistry from UC Berkeley, and had graduate training
in organic chemistry in the PhD program in the Department of Chemistry at Berkeley.

Barry Ticho, MD & PhD, Head of External R&D Innovations, Pfizer, leads external Cardiovascular and Metabolic Scientific Innovation at Pfizer.  Barry has of 15 years of drug development experience in the areas of cardiology, autoimmune disease, neurodegenerative disease, pediatrics and diabetes.  Prior to Pfizer, Barry was Vice President of Clinical Development at Biogen Idec where he established and supervised the Cardiopulmonary Therapeutic Area franchise for the company.  He also led Clinical Development for the Tysabri program.  He held a previous position in Clinical Pharmacology at Merck & Co.  Barry obtained his MD and PhD degrees from the University of Chicago and completed a Pediatric Cardiology fellowship at Children's Hospital of Boston.  He was on clinical staff at Massachusetts General Hospital and conducted laboratory research in the regulation of cardiac development.

James Wilkins, PhD, has been involved in the biotechnology industry on a technical and managerial level for over 25 years. He was Vice President of Process Development and Manufacturing at Alexion Pharmaceuticals (ALXN) and oversaw development of its current blockbuster monoclonal antibody drug, Eculizumab along with a related drug, a single chain antibody, Pexelizumab. Jim was Director of Technology Assessment and Process Development at Genentech until 2009 and was CMC team leader for second generation Anti CD-20 antibody development and manufacturing. He joined Sensorin in 2009 as Chief Technology Officer, where he developed sensors to monitor Biotechnology production processes. Jim also served as Professor of Chemical Engineering at Yale. He earned his B.A. at University of Texas at Austin; his Ph.D. at University of Tennessee; and was a post-doctoral fellow and faculty member in the Thomas Jenkins Department of Biophysics at the Johns Hopkins University.

Scott M. Matthews leads Castlight Health's Product Marketing organization.  Scott’s oversees Castlight’s enterprise product marketing team as well as Castlight’s employee communications practice, which focuses on empowering employees to become engaged consumers of health care.  Scott is board member of the National Business Group on Health's National Leadership Committee on Consumerism and Engagement (NLCCE) and is the author of the whitepaper “Six Drivers of Employee Engagement”.  Prior to Castlight Health, Scott held positions at Phreesia, McKinsey & Company, Accenture, and IBM. Scott holds an MBA with honors from the Wharton School at the University of Pennsylvania and a BS in Computer Sciences with honors, Phi Beta Kappa, from the University of Texas at Austin.



We are going to have the panel discussion and networking reception on Wednesday, January 14. The meeting will be held at the University Club of San Francisco in Nob Hill, a few blocks from the JPM Conference Hotel in Union Square

We will have cocktails @ 6 pm. – 7 pm and panel discussion @ 7 pm. – 9 pm.


Event Contact
Maggie Wu MBA, 1987
maggie_wu@yahoo.com
9258762477